STEMI Clinical Trials

504 recruitingLast updated: June 18, 2026

There are 504 actively recruiting stemi clinical trials across 80 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Paris, France, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


STEMI Trials at a Glance

504 actively recruiting trials for stemi are listed on ClinicalTrialsFinder across 6 cities in 80 countries. The largest study group is Phase 1 with 123 trials, with the heaviest enrollment activity in New York, Paris, and Houston. Lead sponsors running stemi studies include AstraZeneca, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and Assistance Publique - Hôpitaux de Paris.

Treatments under study

About STEMI Clinical Trials

Looking for clinical trials for STEMI? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new STEMI trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about STEMI clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 504 trials

Recruiting
Not Applicable

LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Heinrich-Heine University, Duesseldorf606 enrolled14 locationsNCT05714930
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Not Applicable

Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI-2 Trial

ST-elevation Myocardial Infarction (STEMI)Primary PCI
Chen Jing6,294 enrolled1 locationNCT07361783
Recruiting
Phase 1

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Rheumatoid ArthritisSystemic Lupus Erythematosus
AbbVie30 enrolled6 locationsNCT07607964
Recruiting
Phase 3

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

Lupus Erythematosus, SystemicNephritis, Lupus
Viatris Innovation GmbH300 enrolled11 locationsNCT07201129
Recruiting
Phase 1Phase 2

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Aggressive NK-cell LeukemiaLGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell Lymphoma+10 more
Dren Bio200 enrolled37 locationsNCT05475925
Recruiting

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

Systemic Lupus Erythematosus (SLE)Primary Ovarian Insufficiency (Poi)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)100 enrolled1 locationNCT05567198
Recruiting

Patient-Centered Assessment of Symptoms and Outcomes

Myalgic Encephalomyelitis/Chronic Fatigue SyndromeCancerFatigue+5 more
National Center for Complementary and Integrative Health (NCCIH)692 enrolled1 locationNCT03952624
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled230 locationsNCT06617325
Recruiting
Phase 1Phase 2

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

CAR-T CellSLESystemic Lupus Erythematosus (SLE)+4 more
Children's Hospital of Philadelphia24 enrolled1 locationNCT06839976
Recruiting
Phase 2

Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis

Digital Ulcers in Systemic Sclerosis
Topadur Pharma AG15 enrolled6 locationsNCT06954597
Recruiting
Phase 1

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled14 locationsNCT06925542
Recruiting
Phase 4

Trial of Belimumab in Early Lupus

Lupus ErythematosusLupus Erythematosus, Systemic
Northwell Health30 enrolled1 locationNCT03543839
Recruiting

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled64 locationsNCT07175285
Recruiting
Phase 1

NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

Refractory Lupus NephritisRefractory Systemic Lupus Erythematosus
Guangdong Provincial People's Hospital18 enrolled1 locationNCT06676631
Recruiting
Phase 3

Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis

Interstitial Lung Disease With Systemic Sclerosis
University Hospital, Tours102 enrolled1 locationNCT06549231
Recruiting
Phase 2

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus
Boehringer Ingelheim405 enrolled139 locationsNCT07409181
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Lupus Erythematosus, Systemic
AstraZeneca150 enrolled18 locationsNCT06897930
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim400 enrolled158 locationsNCT06806592
Recruiting
Phase 1

US Zamto-cel Autoimmune Diseases

Systemic Lupus ErythematosusDiffuse Cutaneous Systemic SclerosisSystemic Sclerosis (SSc)+1 more
Miltenyi Biomedicine GmbH48 enrolled1 locationNCT06708845